Elizabeth McFarland
Concepts (385)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 50 | 2026 | 3017 | 3.150 |
Why?
| | HIV-1 | 27 | 2026 | 895 | 2.840 |
Why?
| | Respiratory Syncytial Virus Vaccines | 6 | 2022 | 38 | 2.290 |
Why?
| | HIV Antibodies | 13 | 2026 | 62 | 2.230 |
Why?
| | Respiratory Syncytial Virus Infections | 6 | 2022 | 130 | 2.110 |
Why?
| | Respiratory Syncytial Virus, Human | 6 | 2022 | 76 | 2.100 |
Why?
| | Infectious Disease Transmission, Vertical | 18 | 2025 | 186 | 2.060 |
Why?
| | Anti-Retroviral Agents | 12 | 2023 | 245 | 1.690 |
Why?
| | Anti-HIV Agents | 13 | 2026 | 859 | 1.530 |
Why?
| | Viral Proteins | 3 | 2020 | 369 | 1.510 |
Why?
| | Antibodies, Neutralizing | 9 | 2026 | 305 | 1.110 |
Why?
| | Antibodies, Viral | 8 | 2022 | 653 | 1.100 |
Why?
| | Colonography, Computed Tomographic | 3 | 2024 | 8 | 0.950 |
Why?
| | Antibodies, Monoclonal | 6 | 2025 | 1448 | 0.840 |
Why?
| | AIDS Vaccines | 8 | 2018 | 53 | 0.840 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2025 | 239 | 0.780 |
Why?
| | Pregnancy Complications, Infectious | 8 | 2016 | 406 | 0.740 |
Why?
| | Gene Deletion | 2 | 2020 | 388 | 0.710 |
Why?
| | Breast Feeding | 4 | 2025 | 444 | 0.630 |
Why?
| | Atazanavir Sulfate | 2 | 2017 | 44 | 0.620 |
Why?
| | HIV Protease Inhibitors | 2 | 2017 | 68 | 0.610 |
Why?
| | Ritonavir | 2 | 2017 | 75 | 0.600 |
Why?
| | Infant, Newborn | 24 | 2026 | 6275 | 0.580 |
Why?
| | HIV Envelope Protein gp120 | 6 | 2017 | 61 | 0.570 |
Why?
| | Vaccines, Attenuated | 6 | 2022 | 130 | 0.560 |
Why?
| | Vaccination | 6 | 2020 | 1467 | 0.550 |
Why?
| | Incidental Findings | 1 | 2018 | 80 | 0.540 |
Why?
| | Infant | 32 | 2026 | 9818 | 0.510 |
Why?
| | Telemedicine | 1 | 2025 | 891 | 0.500 |
Why?
| | Nelfinavir | 1 | 2016 | 9 | 0.500 |
Why?
| | Radiation Dosage | 1 | 2018 | 191 | 0.500 |
Why?
| | Lopinavir | 1 | 2016 | 31 | 0.490 |
Why?
| | Syncope | 1 | 2016 | 56 | 0.480 |
Why?
| | Bradycardia | 1 | 2016 | 52 | 0.480 |
Why?
| | Patient Dropouts | 1 | 2016 | 65 | 0.480 |
Why?
| | Lyme Disease | 1 | 2016 | 61 | 0.470 |
Why?
| | Health Resources | 1 | 2016 | 129 | 0.450 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 113 | 0.440 |
Why?
| | HIV | 5 | 2014 | 250 | 0.410 |
Why?
| | Patient Compliance | 2 | 2018 | 610 | 0.380 |
Why?
| | Humans | 76 | 2026 | 141187 | 0.380 |
Why?
| | Immunogenicity, Vaccine | 4 | 2021 | 34 | 0.380 |
Why?
| | Referral and Consultation | 1 | 2018 | 798 | 0.370 |
Why?
| | Child | 37 | 2025 | 22308 | 0.370 |
Why?
| | Female | 50 | 2026 | 75515 | 0.370 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2005 | 174 | 0.350 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 1110 | 0.350 |
Why?
| | Virus Replication | 4 | 2020 | 532 | 0.340 |
Why?
| | Adolescent | 28 | 2025 | 22007 | 0.340 |
Why?
| | Male | 41 | 2026 | 69783 | 0.330 |
Why?
| | Lymphocyte Activation | 5 | 2017 | 1150 | 0.310 |
Why?
| | Young Adult | 14 | 2026 | 13673 | 0.290 |
Why?
| | Viral Load | 9 | 2017 | 506 | 0.270 |
Why?
| | HIV Seropositivity | 2 | 2023 | 127 | 0.270 |
Why?
| | Bone Density | 2 | 2025 | 494 | 0.270 |
Why?
| | Double-Blind Method | 3 | 2020 | 1983 | 0.260 |
Why?
| | RNA, Viral | 8 | 2023 | 693 | 0.250 |
Why?
| | Antibodies, Bacterial | 2 | 2018 | 146 | 0.240 |
Why?
| | Dyslipidemias | 2 | 2017 | 175 | 0.230 |
Why?
| | Bone Development | 1 | 2025 | 54 | 0.230 |
Why?
| | Antiretroviral Therapy, Highly Active | 6 | 2017 | 285 | 0.230 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 209 | 0.220 |
Why?
| | Immunoglobulin G | 3 | 2022 | 900 | 0.220 |
Why?
| | Diverticulum | 1 | 2024 | 12 | 0.210 |
Why?
| | Viremia | 3 | 2011 | 150 | 0.210 |
Why?
| | Gene Products, gag | 2 | 1994 | 38 | 0.210 |
Why?
| | Mammography | 1 | 2025 | 159 | 0.200 |
Why?
| | Child, Preschool | 21 | 2022 | 11457 | 0.200 |
Why?
| | Squalene | 3 | 2017 | 7 | 0.200 |
Why?
| | Pregnancy | 11 | 2023 | 7070 | 0.190 |
Why?
| | Complementarity Determining Regions | 1 | 2002 | 51 | 0.190 |
Why?
| | Prospective Studies | 5 | 2025 | 7739 | 0.190 |
Why?
| | Drug Resistance, Viral | 2 | 2016 | 120 | 0.180 |
Why?
| | CD4 Lymphocyte Count | 4 | 2017 | 284 | 0.180 |
Why?
| | Half-Life | 1 | 2021 | 146 | 0.180 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2021 | 40 | 0.180 |
Why?
| | Feasibility Studies | 1 | 2025 | 1018 | 0.180 |
Why?
| | Mitochondrial Diseases | 1 | 2021 | 94 | 0.170 |
Why?
| | Immunization Schedule | 2 | 2018 | 203 | 0.170 |
Why?
| | Colorado | 4 | 2025 | 4610 | 0.170 |
Why?
| | Drug Therapy, Combination | 4 | 2017 | 1040 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 335 | 0.170 |
Why?
| | RNA, Small Untranslated | 1 | 2020 | 12 | 0.170 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 180 | 0.170 |
Why?
| | T-Lymphocytes | 2 | 2009 | 2002 | 0.160 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 2 | 2017 | 16 | 0.160 |
Why?
| | Pilot Projects | 1 | 2025 | 1820 | 0.160 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 188 | 0.160 |
Why?
| | Cytokines | 2 | 2021 | 2098 | 0.150 |
Why?
| | Point Mutation | 1 | 2020 | 237 | 0.150 |
Why?
| | Body Temperature | 1 | 2020 | 224 | 0.150 |
Why?
| | Haemophilus Vaccines | 2 | 2018 | 30 | 0.150 |
Why?
| | Immunocompromised Host | 2 | 2000 | 203 | 0.150 |
Why?
| | Immunologic Memory | 2 | 2021 | 360 | 0.150 |
Why?
| | Insulin Resistance | 3 | 2019 | 1225 | 0.150 |
Why?
| | Darunavir | 1 | 2017 | 19 | 0.140 |
Why?
| | Interleukin-12 | 1 | 1998 | 123 | 0.140 |
Why?
| | Metabolic Syndrome | 1 | 2021 | 349 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2011 | 918 | 0.140 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 364 | 0.130 |
Why?
| | Therapeutic Equipoise | 1 | 2017 | 2 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 2064 | 0.130 |
Why?
| | Interferon-gamma | 5 | 2012 | 792 | 0.130 |
Why?
| | Lymphopoiesis | 1 | 2017 | 26 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 298 | 0.130 |
Why?
| | Immunoglobulin A | 2 | 2017 | 214 | 0.130 |
Why?
| | Uganda | 1 | 2017 | 87 | 0.130 |
Why?
| | Receptors, CCR5 | 1 | 2017 | 60 | 0.130 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 157 | 0.130 |
Why?
| | CD4-CD8 Ratio | 1 | 2016 | 24 | 0.130 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 1 | 2016 | 11 | 0.130 |
Why?
| | Adult | 16 | 2026 | 39177 | 0.120 |
Why?
| | Adoption | 1 | 2016 | 30 | 0.120 |
Why?
| | Virus Latency | 1 | 2016 | 80 | 0.120 |
Why?
| | Cohort Studies | 8 | 2025 | 5799 | 0.120 |
Why?
| | Mothers | 3 | 2017 | 785 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2016 | 244 | 0.110 |
Why?
| | Chickenpox Vaccine | 1 | 2015 | 74 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2018 | 287 | 0.110 |
Why?
| | Body Height | 2 | 2017 | 196 | 0.110 |
Why?
| | Zimbabwe | 2 | 2025 | 61 | 0.110 |
Why?
| | Gene Products, env | 1 | 1994 | 6 | 0.110 |
Why?
| | Disease Susceptibility | 1 | 2017 | 352 | 0.110 |
Why?
| | Haemophilus influenzae type b | 1 | 2014 | 12 | 0.110 |
Why?
| | Chickenpox | 1 | 2015 | 81 | 0.110 |
Why?
| | Bacterial Capsules | 1 | 2014 | 31 | 0.110 |
Why?
| | Antibody Affinity | 1 | 2014 | 60 | 0.110 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2000 | 235 | 0.110 |
Why?
| | Cote d'Ivoire | 2 | 2025 | 9 | 0.110 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.110 |
Why?
| | Vaccines, Synthetic | 4 | 2005 | 139 | 0.110 |
Why?
| | South Africa | 2 | 2025 | 240 | 0.110 |
Why?
| | Developing Countries | 1 | 2016 | 317 | 0.100 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2002 | 226 | 0.100 |
Why?
| | Puberty, Delayed | 1 | 2013 | 9 | 0.100 |
Why?
| | Intestines | 1 | 2017 | 357 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 4 | 2013 | 573 | 0.100 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1993 | 34 | 0.100 |
Why?
| | Mycobacterium chelonae | 1 | 1993 | 9 | 0.100 |
Why?
| | Vaccines | 1 | 2018 | 406 | 0.100 |
Why?
| | Lipids | 1 | 2017 | 689 | 0.100 |
Why?
| | Patient Selection | 1 | 2017 | 688 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2023 | 16273 | 0.100 |
Why?
| | Lamivudine | 3 | 2023 | 65 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 802 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2250 | 0.090 |
Why?
| | Mitochondria | 2 | 2021 | 967 | 0.090 |
Why?
| | Cell Movement | 1 | 2017 | 990 | 0.090 |
Why?
| | Cardiovascular Diseases | 2 | 2016 | 2087 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2019 | 600 | 0.090 |
Why?
| | STAT1 Transcription Factor | 1 | 2012 | 71 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1052 | 0.090 |
Why?
| | Child Development | 1 | 2017 | 498 | 0.090 |
Why?
| | Body Fat Distribution | 1 | 2011 | 48 | 0.090 |
Why?
| | Polysorbates | 3 | 2017 | 41 | 0.090 |
Why?
| | Body Weight | 2 | 2017 | 996 | 0.090 |
Why?
| | Mycobacterium avium Complex | 1 | 2012 | 87 | 0.090 |
Why?
| | Epitopes | 2 | 2022 | 477 | 0.090 |
Why?
| | Cost-Benefit Analysis | 2 | 2025 | 618 | 0.090 |
Why?
| | United States | 9 | 2023 | 15220 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1143 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 703 | 0.080 |
Why?
| | Interleukin-2 | 2 | 2003 | 453 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 385 | 0.080 |
Why?
| | Exercise | 1 | 2021 | 2103 | 0.080 |
Why?
| | Freezing | 1 | 2009 | 88 | 0.070 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 662 | 0.070 |
Why?
| | Absorptiometry, Photon | 2 | 2025 | 266 | 0.070 |
Why?
| | Blood | 1 | 2009 | 113 | 0.070 |
Why?
| | Algorithms | 1 | 2016 | 1763 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3166 | 0.070 |
Why?
| | Staff Development | 1 | 2009 | 60 | 0.070 |
Why?
| | Age Factors | 4 | 2019 | 3292 | 0.070 |
Why?
| | T-Lymphocyte Subsets | 2 | 2002 | 415 | 0.070 |
Why?
| | Biomarkers | 4 | 2021 | 4174 | 0.070 |
Why?
| | Lymphocyte Subsets | 2 | 2009 | 88 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 855 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2902 | 0.070 |
Why?
| | Specimen Handling | 1 | 2009 | 182 | 0.070 |
Why?
| | Enterovirus A, Human | 1 | 2007 | 13 | 0.070 |
Why?
| | Faculty | 1 | 2009 | 154 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 78 | 0.070 |
Why?
| | Adipose Tissue | 1 | 2011 | 647 | 0.070 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2007 | 77 | 0.060 |
Why?
| | Polymerase Chain Reaction | 4 | 2011 | 1056 | 0.060 |
Why?
| | DNA, Viral | 2 | 2000 | 366 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2009 | 1197 | 0.060 |
Why?
| | Academic Medical Centers | 1 | 2009 | 528 | 0.060 |
Why?
| | False Negative Reactions | 1 | 2025 | 61 | 0.060 |
Why?
| | Isoantigens | 1 | 1984 | 17 | 0.060 |
Why?
| | Enterovirus Infections | 1 | 2007 | 172 | 0.060 |
Why?
| | Cell Line | 3 | 2012 | 2885 | 0.060 |
Why?
| | Medical Audit | 1 | 2025 | 78 | 0.060 |
Why?
| | C-Reactive Protein | 2 | 2021 | 418 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2006 | 269 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 857 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5200 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2007 | 419 | 0.050 |
Why?
| | Confusion | 1 | 2024 | 30 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2007 | 824 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1662 | 0.050 |
Why?
| | Thymus Gland | 1 | 1984 | 319 | 0.050 |
Why?
| | Tablets | 1 | 2023 | 41 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2024 | 238 | 0.050 |
Why?
| | Regression Analysis | 2 | 2021 | 1020 | 0.050 |
Why?
| | Risk Factors | 4 | 2021 | 10438 | 0.050 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2022 | 58 | 0.050 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 23 | 0.050 |
Why?
| | Immunophenotyping | 2 | 1994 | 329 | 0.050 |
Why?
| | Zidovudine | 2 | 2015 | 79 | 0.050 |
Why?
| | Clone Cells | 1 | 2002 | 266 | 0.050 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2001 | 85 | 0.050 |
Why?
| | Cough | 1 | 2022 | 129 | 0.040 |
Why?
| | Vaccines, Subunit | 1 | 2001 | 50 | 0.040 |
Why?
| | Emtricitabine | 1 | 2023 | 205 | 0.040 |
Why?
| | Pyridones | 1 | 2023 | 176 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 51 | 0.040 |
Why?
| | Tenofovir | 1 | 2023 | 276 | 0.040 |
Why?
| | Ganciclovir | 1 | 2000 | 53 | 0.040 |
Why?
| | Lung | 1 | 2014 | 4134 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 84 | 0.040 |
Why?
| | Computer Simulation | 1 | 2005 | 1015 | 0.040 |
Why?
| | Africa | 1 | 2020 | 119 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 165 | 0.040 |
Why?
| | Adjuvants, Immunologic | 2 | 2017 | 238 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2021 | 110 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 129 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 2058 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5636 | 0.040 |
Why?
| | HIV Seronegativity | 1 | 2019 | 30 | 0.040 |
Why?
| | HLA-D Antigens | 1 | 1999 | 32 | 0.040 |
Why?
| | Risk | 1 | 2021 | 904 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2000 | 197 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3588 | 0.040 |
Why?
| | Prevalence | 2 | 2016 | 2772 | 0.040 |
Why?
| | Cholesterol, HDL | 1 | 2019 | 196 | 0.040 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1998 | 51 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1998 | 38 | 0.040 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 27 | 0.040 |
Why?
| | Vaccines, Combined | 1 | 2018 | 49 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 696 | 0.040 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2018 | 28 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2158 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 1052 | 0.040 |
Why?
| | Hepatitis B Vaccines | 1 | 2018 | 43 | 0.040 |
Why?
| | Mutation | 3 | 2018 | 4013 | 0.030 |
Why?
| | Drug Resistance, Microbial | 2 | 2000 | 65 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2929 | 0.030 |
Why?
| | Colon | 1 | 2020 | 300 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2019 | 273 | 0.030 |
Why?
| | Case Management | 1 | 2018 | 67 | 0.030 |
Why?
| | Antigens, Viral | 1 | 1998 | 179 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 405 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 2019 | 361 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1998 | 184 | 0.030 |
Why?
| | Immune Tolerance | 1 | 1999 | 368 | 0.030 |
Why?
| | Treatment Adherence and Compliance | 1 | 2017 | 27 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 514 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 633 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3348 | 0.030 |
Why?
| | Lymphocyte Count | 2 | 2009 | 167 | 0.030 |
Why?
| | Cell Division | 1 | 1998 | 798 | 0.030 |
Why?
| | Uncertainty | 1 | 2017 | 138 | 0.030 |
Why?
| | Treatment Failure | 1 | 2017 | 354 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 338 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 18 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2015 | 166 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 131 | 0.030 |
Why?
| | Genes, pol | 1 | 1994 | 7 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2017 | 217 | 0.030 |
Why?
| | Malnutrition | 1 | 2016 | 85 | 0.030 |
Why?
| | Maternal Exposure | 1 | 2017 | 202 | 0.030 |
Why?
| | Coinfection | 1 | 2016 | 137 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2000 | 747 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1556 | 0.030 |
Why?
| | Vaccines, Conjugate | 1 | 2014 | 64 | 0.030 |
Why?
| | Counseling | 1 | 2018 | 398 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 157 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2021 | 11120 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2008 | 4208 | 0.030 |
Why?
| | Sexual and Gender Minorities | 1 | 2018 | 234 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 386 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 177 | 0.030 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 172 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2013 | 62 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2013 | 42 | 0.030 |
Why?
| | Tuberculosis, Cutaneous | 1 | 1993 | 3 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2015 | 208 | 0.020 |
Why?
| | HIV Reverse Transcriptase | 1 | 1993 | 31 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1993 | 75 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 178 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 513 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2892 | 0.020 |
Why?
| | CD3 Complex | 1 | 1993 | 106 | 0.020 |
Why?
| | Drug Administration Schedule | 2 | 2008 | 771 | 0.020 |
Why?
| | Blood Pressure | 1 | 2019 | 1748 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 2013 | 200 | 0.020 |
Why?
| | Lymphocytes | 1 | 1994 | 398 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 211 | 0.020 |
Why?
| | P-Selectin | 1 | 2011 | 28 | 0.020 |
Why?
| | E-Selectin | 1 | 2011 | 57 | 0.020 |
Why?
| | Heteroduplex Analysis | 1 | 2011 | 1 | 0.020 |
Why?
| | Tuberculosis, Pulmonary | 1 | 1993 | 142 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1653 | 0.020 |
Why?
| | Antigens, CD | 1 | 1994 | 539 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 117 | 0.020 |
Why?
| | Blood Transfusion | 1 | 1994 | 392 | 0.020 |
Why?
| | Hyperlipidemias | 1 | 2011 | 125 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2255 | 0.020 |
Why?
| | Cell Proliferation | 2 | 2009 | 2504 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2012 | 194 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2012 | 196 | 0.020 |
Why?
| | Nontuberculous Mycobacteria | 1 | 1993 | 205 | 0.020 |
Why?
| | Fibrinogen | 1 | 2011 | 180 | 0.020 |
Why?
| | Cell Adhesion Molecules | 1 | 2011 | 179 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2017 | 666 | 0.020 |
Why?
| | Cross Infection | 1 | 1993 | 254 | 0.020 |
Why?
| | Infant, Premature | 1 | 1994 | 597 | 0.020 |
Why?
| | Pokeweed Mitogens | 1 | 2009 | 7 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1498 | 0.020 |
Why?
| | L-Selectin | 1 | 2009 | 24 | 0.020 |
Why?
| | Human Experimentation | 1 | 2009 | 14 | 0.020 |
Why?
| | Tetanus | 1 | 2009 | 27 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2009 | 90 | 0.020 |
Why?
| | Candida | 1 | 2009 | 41 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 3004 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1490 | 0.020 |
Why?
| | Meningitis, Aseptic | 1 | 2007 | 13 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2007 | 31 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1768 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2011 | 792 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2007 | 92 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 376 | 0.020 |
Why?
| | Paralysis | 1 | 2007 | 70 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 457 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2007 | 127 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2012 | 858 | 0.020 |
Why?
| | Kinetics | 1 | 2010 | 1652 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1859 | 0.020 |
Why?
| | Respiratory System | 1 | 2007 | 157 | 0.020 |
Why?
| | Immunoglobulin A, Secretory | 1 | 2005 | 9 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1129 | 0.010 |
Why?
| | Phosphates | 1 | 1987 | 181 | 0.010 |
Why?
| | Muscles | 1 | 1987 | 333 | 0.010 |
Why?
| | Encephalitis | 1 | 2007 | 137 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2007 | 204 | 0.010 |
Why?
| | Mucous Membrane | 1 | 2005 | 125 | 0.010 |
Why?
| | Chemistry, Physical | 1 | 1984 | 38 | 0.010 |
Why?
| | Antigen-Antibody Reactions | 1 | 1984 | 54 | 0.010 |
Why?
| | Chemical Phenomena | 1 | 1984 | 82 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1478 | 0.010 |
Why?
| | Myasthenia Gravis | 1 | 1984 | 23 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1984 | 72 | 0.010 |
Why?
| | Saliva | 1 | 2005 | 245 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1984 | 330 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2746 | 0.010 |
Why?
| | Epithelium | 1 | 1984 | 316 | 0.010 |
Why?
| | Aging | 2 | 2003 | 1892 | 0.010 |
Why?
| | Blood Glucose | 1 | 2013 | 2269 | 0.010 |
Why?
| | Body Mass Index | 1 | 2011 | 2382 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 417 | 0.010 |
Why?
| | Middle Aged | 2 | 2020 | 34434 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1993 | 1865 | 0.010 |
Why?
| | Reference Values | 1 | 2003 | 805 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1274 | 0.010 |
Why?
| | Suspensions | 1 | 2000 | 29 | 0.010 |
Why?
| | Capsules | 1 | 2000 | 39 | 0.010 |
Why?
| | Urban Population | 1 | 2003 | 485 | 0.010 |
Why?
| | Drug Tolerance | 1 | 2000 | 105 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2000 | 163 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5144 | 0.010 |
Why?
| | Administration, Oral | 1 | 2000 | 803 | 0.010 |
Why?
| | Epithelial Cells | 1 | 1984 | 1110 | 0.010 |
Why?
| | Immunization | 1 | 2000 | 406 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6956 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2000 | 1357 | 0.010 |
Why?
| | Macrophages | 1 | 1984 | 1561 | 0.010 |
Why?
| | Tail | 1 | 1987 | 29 | 0.000 |
Why?
| | Mice | 1 | 1984 | 18048 | 0.000 |
Why?
| | Phosphocreatine | 1 | 1987 | 45 | 0.000 |
Why?
| | Salamandridae | 1 | 1987 | 33 | 0.000 |
Why?
| | Animals | 2 | 1987 | 37657 | 0.000 |
Why?
| | Aged | 1 | 1984 | 24574 | 0.000 |
Why?
| | Adenosine Triphosphate | 1 | 1987 | 492 | 0.000 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1987 | 614 | 0.000 |
Why?
|
|
McFarland's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|